Get the Stockscreener App
7.13
4.30%
-0.32
After Hours:
7.10
-0.03
-0.42%
Organon Co stock is traded at $7.13, with a volume of 5.31M.
It is down -4.30% in the last 24 hours and down -22.84% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$7.45
Open:
$7.44
24h Volume:
5.31M
Relative Volume:
0.98
Market Cap:
$1.85B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.6484
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-6.43%
1M Performance:
-22.84%
6M Performance:
-18.61%
1Y Performance:
-51.60%
1-Day Range:
$7.05
$7.52
1-Week Range:
$7.05
$7.88
52-Week Range:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.13 | 1.94B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,043.29 | 939.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
203.07 | 487.91B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.45 | 411.64B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
124.36 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
94.97 | 235.92B | 63.90B | 19.05B | 13.05B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Co. (7XP) stock profit from AI boomChart Signals & Consistent Profit Alerts - newser.com
Discipline and Rules-Based Execution in OGN Response - news.stocktradersdaily.com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld MedTech
Co. (7XP) stock profit from automation waveWeekly Trade Recap & Fast Gain Swing Alerts - newser.com
Organon Executive Chairman of the Board Acquires 525% More Stock - simplywall.st
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - Yahoo Finance
Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight - GlobeNewswire Inc.
Organon, Shanghai Henlius Biotech Says FDA Clears Poherdy as Pertuzumab Biosimilar - MarketScreener
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call - The Globe and Mail
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US - FinancialContent
The 5 Most Interesting Analyst Questions From Organon's Q3 Earnings Call - Finviz
Organon Q3 2025 Earnings: Revenue & EPS Beat EstimatesNews and Statistics - IndexBox
Organon (OGN) Price Target Decreased by 10.77% to 9.86 - Nasdaq
Are Margin Pressures Reshaping Organon’s (OGN) Long-Term Competitive Position? - simplywall.st
Organon & Co. (OGN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - Business Wire
Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67 - simplywall.st
Executive Chairman of the Board of Organon Carrie Cox Buys 525% More Shares - Yahoo Finance
First Perjeta Biosimilar Is Approved In The US For Henlius And Organon - Citeline News & Insights
Executive Chair Makes Bold Move with Major Organon Stock Purchase - TipRanks
Organon Shares Face Mounting Pressure Amid Strategic Shifts - AD HOC NEWS
Laborie to acquire Organon’s JADA System for $465M - NJBIZ
Bank of America Securities Sticks to Its Sell Rating for Organon (OGN) - The Globe and Mail
Organon (OGN): Assessing Valuation After Recent Share Price Rebound - Yahoo Finance
Organon (OGN) Stock Trades Down, Here Is Why - The Globe and Mail
Is Organon’s 15% Share Price Jump a Sign of Real Value in 2025? - Yahoo Finance
Organon & Co. Earnings Call: Mixed Results Amid Challenges - TipRanks
JP Morgan Lowers Price Target for Organon (OGN) to $12.00 | OGN Stock News - GuruFocus
Organon & Co. (OGN) Climbs 13.7% Ahead of Dividends - Insider Monkey
Organon: Q3 Earnings Lift Struggling StockBut Not For Long, I Suspect (NYSE:OGN) - Seeking Alpha
Organon Co earnings beat by $0.07, revenue topped estimates - Investing.com Philippines
Organon Analysts Cut Their Forecasts Following Q3 Results - Benzinga
Organon lowers 2025 revenue guidance to $6.2B–$6.25B amid U.S. Nexplanon headwinds and Jada divestiture - MSN
Organon & Co. (NYSE:OGN) Q3 2025 Earnings Call Transcript - MSN
Organon (OGN) Analyst Rating Update: Morgan Stanley Lowers Price Target | OGN Stock News - GuruFocus
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Cuts Target Price to $9 - 富途牛牛
Organon price target lowered to $9 from $10 at Morgan Stanley - TipRanks
Organon & Co (OGN) Q3 2025 Earnings Call Highlights: Strong Biosimilars Performance Amidst ... By GuruFocus - Investing.com Canada
Earnings call transcript: Organon Q3 2025 beats forecasts, stock surges By Investing.com - Investing.com Philippines
Organon to divest its JADA® System for USD 465M to Laborie - Medical Buyer
Organon Reports Results for the Third Quarter Ended September 30, 2025 - BioSpace
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration - Yahoo Finance
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Organon & Co. Reports Modest Q3 Revenue Growth - TipRanks
Organon (OGN) Q3 Earnings and Revenues Beat Estimates - sharewise.com
Organon: Q3 Earnings Snapshot - Chron
[Form 4] Organon & Co. Insider Trading Activity - Stock Titan
Officer Arjona Ferreira Acquires 4,139 Of Organon & Co [OGN] - TradingView
Organon to sell Jada postpartum haemorrhage device - FemTech World
Organon & Co.: Is It Time to Buy or Watch? - StocksToTrade
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):